(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.81%) $83.17
(1.04%) $1.943
(-0.35%) $2 339.10
(-0.05%) $27.52
(0.61%) $927.70
(-0.26%) $0.932
(-0.27%) $10.99
(-0.29%) $0.798
(0.25%) $92.11
Live Chart Being Loaded With Signals
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally...
Stats | |
---|---|
Dagens volum | 34.61M |
Gjennomsnittsvolum | 38.96M |
Markedsverdi | 79.69B |
EPS | HKD0 ( 2024-03-19 ) |
Neste inntjeningsdato | ( HKD0.150 ) 2024-05-22 |
Last Dividend | HKD0.140 ( 2023-09-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.66 |
ATR14 | HKD0.00800 (0.12%) |
Volum Korrelasjon
CSPC Pharmaceutical Group Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
CSPC Pharmaceutical Group Korrelasjon - Valuta/Råvare
CSPC Pharmaceutical Group Økonomi
Annual | 2023 |
Omsetning: | HKD34.75B |
Bruttogevinst: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2023 |
Omsetning: | HKD34.75B |
Bruttogevinst: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
FY | 2022 |
Omsetning: | HKD35.98B |
Bruttogevinst: | HKD25.88B (71.94 %) |
EPS: | HKD0.590 |
FY | 2021 |
Omsetning: | HKD27.87B |
Bruttogevinst: | HKD21.14B (75.84 %) |
EPS: | HKD0.470 |
Financial Reports:
No articles found.
CSPC Pharmaceutical Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.110 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0365 | 2003-08-28 |
Last Dividend | HKD0.140 | 2023-09-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD1.673 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.33 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.89 | |
Div. Directional Score | 8.74 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9909.HK | Ex Dividend Knight | 2023-11-24 | Semi-Annually | 0 | 0.00% | |
2161.HK | Ex Dividend Junior | 2023-08-15 | Annually | 0 | 0.00% | |
1161.HK | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
0239.HK | Ex Dividend Knight | 2023-09-29 | Semi-Annually | 0 | 0.00% | |
3866.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1731.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
0771.HK | Ex Dividend Junior | 2023-05-31 | Sporadic | 0 | 0.00% | |
2327.HK | Ex Dividend Junior | 2023-08-03 | Sporadic | 0 | 0.00% | |
1290.HK | Ex Dividend Junior | 2023-06-14 | Sporadic | 0 | 0.00% | |
0363.HK | Ex Dividend Knight | 2023-06-01 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.189 | 1.500 | 6.23 | 9.34 | [0 - 0.5] |
returnOnAssetsTTM | 0.150 | 1.200 | 5.01 | 6.01 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.325 | -1.000 | 6.75 | -6.75 | [0 - 1] |
currentRatioTTM | 2.63 | 0.800 | 1.867 | 1.494 | [1 - 3] |
quickRatioTTM | 2.27 | 0.800 | 1.336 | 1.069 | [0.8 - 2.5] |
cashRatioTTM | 1.180 | 1.500 | 4.56 | 6.83 | [0.2 - 2] |
debtRatioTTM | 0.0151 | -1.500 | 9.75 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 362.23 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.698 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0210 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.707 | 1.000 | 1.551 | 1.551 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.232 | 1.000 | 7.36 | 7.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.82 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.794 | 0.800 | 8.04 | 6.43 | [0.5 - 2] |
Total Score | 11.58 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.29 | 1.000 | 9.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.79 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.698 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.325 | 1.500 | 6.75 | -6.75 | [0 - 1] |
pegRatioTTM | -0.252 | 1.500 | -5.01 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.205 | 1.000 | 7.37 | 0 | [0.1 - 0.5] |
Total Score | 5.89 |
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.